Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger
Recce Pharmaceuticals (ASX:RCE) has been on a tear this year. It's developing anti-infective, R327, with clinical results across Diabetic Foot Infection, Acute Bacterial Skin & Skin Structure Infection, and, Urosepsis/UTIs which point to a potential commercial value proposition. It also has a recent key relationship in Indonesia.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
Tag | Subject | ||||||
---|---|---|---|---|---|---|---|
AOM | Palatine Energy pty ltd | 26/11/17 | 1 | 2.3K | |||
|
|||||||
AOM | Ann: Becoming a substantial holder | 17/04/14 | 0 | 1.1K | |||
|
|||||||
AOM | Ann: Appendix 3B | 15/04/14 | 0 | 1.0K | |||
|
|||||||
AOM | Ann: RHS audited accounts FY13 | 15/04/14 | 0 | 992 | |||
|
|||||||
AOM | Ann: RHS audited accounts FY12 | 15/04/14 | 0 | 995 | |||
|
|||||||
AOM | Ann: RHS audited accounts FY11 | 15/04/14 | 0 | 568 | |||
|
|||||||
AOM | Ann: Employee Share Option Plan Rules | 15/04/14 | 0 | 513 | |||
|
|||||||
AOM | Ann: Securities Trading Policy | 15/04/14 | 0 | 483 | |||
|
See All Discussions